Cancer gene discovery in hepatocellular carcinoma

Journal of Hepatology

Volumn 52, Issue 6, 2010, Pages 921-929

  Zender, Lars ^a,b   Villanueva, Augusto ^c   Tovar, Victoria ^c   Sia, Daniela ^c   Chiang, Derek Y ^d   Llovet, Josep M ^c,e,f  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c HCC Translational Research Laboratory   (Spain)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Hepatocellular carcinoma; High throughput technology; Mouse models; RNA interference; Signaling pathways

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR 6; GEFITINIB; INTERFERON; INTERLEUKIN 6; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RAS PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; SORAFENIB; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN;

ALCOHOL ABUSE; ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CANCER INCIDENCE; CANCER RISK; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC RISK; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC THERAPY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; SIGNAL TRANSDUCTION;

EID: 77952528214     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.12.034     Document Type: Review

References (103)

1. Llovet J., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., and Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27 (2007) 55-76
3. Llovet J., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
4. Llovet J., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
5. Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008) 1972-1983 83 e1-e11
6. Chiang D.Y., Villanueva A., Hoshida Y., Peix J., Newell P., Minguez B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 (2008) 6779-6788
7. Tanabe K.K., Lemoine A., Finkelstein D.M., Kawasaki H., Fujii T., Chung R.T., et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299 (2008) 53-60
8. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008) 1995-2004
9. Keng V.W., Villanueva A., Chiang D.Y., Dupuy A.J., Ryan B.J., Matise I., et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 27 (2009) 264-274
10. Schiffer E., Housset C., Cacheux W., Wendum D., Desbois-Mouthon C., Rey C., et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41 (2005) 307-314
11. Breuhahn K., Longerich T., and Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25 (2006) 3787-3800
12. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., and Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis 1. Cancer Res 53 (1993) 1719-1723
13. Philip P. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23 (2005) 6657-6663
14. Thomas M., Chadha R., Glover K., Wang X., Morris J., Brown T., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110 (2007) 1059-1067
15. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8 (2008) 915-928
16. Sachdev D., and Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6 (2007) 1-12
17. Tang S.H., Yang D.H., Huang W., Zhou H.K., Lu X.H., and Ye G. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res 12 (2006) 4171-4177
18. De Souza A.T., Hankins G.R., Washington M.K., Orton T.C., and Jirtle R.L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11 (1995) 447-449
19. Hanafusa T., Yumoto Y., Nouso K., Nakatsukasa H., Onishi T., Fujikawa T., et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176 (2002) 149-158
20. Tovar V., Alsinet C., Villanueva A., Hoshida Y., Chiang D., Sole M., et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52 (2010) 550-559
21. Kim S.O., Park J.G., and Lee Y.I. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 56 (1996) 3831-3836
22. Takayama H., Larochelle W.J., Sharp R., Otsuka T., Kriebel P., Anver M., et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. PNAS 94 (1997) 701-706
23. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67 (2007) 2081-2088
24. Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7 (2008) 504-516
25. Ueki T., Fujimoto J., Suzuki T., Yamamoto H., and Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25 (1997) 862-866
26. Kaposi-Novak P. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116 (2006) 1582-1595
27. Salvi A., Arici B., Portolani N., Giulini S.M., De P.G., and Barlati S. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol 31 (2007) 451-460
28. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
29. Karreth F.A., and Tuveson D.A. Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev 19 (2009) 4-11
30. Calvisi D., Ladu S., Gorden A., Farina M., Conner E., Lee J., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
31. Newell P., Toffanin S., Villanueva A., Chiang D.Y., Minguez B., Cabellos L., et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 51 (2009) 725-733
32. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103 (2005) 307-312
33. Sarbassov D.D., Ali S.M., and Sabatini D.M. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17 (2005) 596-603
34. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006) 729-734
35. Guertin D.A., Stevens D.M., Saitoh M., Kinkel S., Crosby K., Sheen J.H., et al. MTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15 (2009) 148-159
36. Treiber G. MTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 9 (2009) 247-261
37. Yang Z. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13 (2008) 153-166
38. Gonzalez C. Spindle orientation, asymmetric division and tumour suppression in Drosophila stem cells. Nat Rev Genet 8 (2007) 462-472
39. Zaret K. Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. Nat Rev Genet 9 (2008) 329-340
40. Zaret K., and Grompe M. Generation and regeneration of cells of the liver and pancreas. Science 322 (2008) 1490-1494
41. Thompson M.D., and Monga S.P. WNT/beta-catenin signaling in liver health and disease. Hepatology 45 (2007) 1298-1305
42. Boyault S., Rickman D.S., de R.A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007) 42-52
43. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461 (2009) 614-620
44. Sicklick J.K., Li Y.X., Jayaraman A., Kannangai R., Qi Y., Vivekanandan P., et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 27 (2006) 748-757
45. Tada M., Kanai F., Tanaka Y., Tateishi K., Ohta M., Asaoka Y., et al. Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res 14 (2008) 3768-3776
46. Lok A.S., Seeff L.B., Morgan T.R., Di Bisceglie A.M., Sterling R.K., Curto T.M., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009) 138-148
47. Naugler W., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007) 121-124
48. Lin L., Amin R., Gallicano G.I., Glasgow E., Jogunoori W., Jessup J.M., et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28 (2009) 961-972
49. Coulouarn C., Factor V.M., and Thorgeirsson S.S. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47 (2008) 2059-2067
50. Elsharkawy A.M., and Mann D.A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46 (2007) 590-597
51. Yoo B.K., Emdad L., Su Z.Z., Villanueva A., Chiang D.Y., Mukhopadhyay N.D., et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 119 (2009) 465-477
52. Haybaeck J., Zeller N., Wolf M.K., Weber A., Wagner U., Kurrer M.O., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16 (2009) 272-273
53. Villanueva A., Savic R., and Llovet J.M. Lymphotoxins: novel targets for HCC. Cancer Cell 16 (2009) 272-273
54. Li X.M., Tang Z.Y., Zhou G., Lui Y.K., and Ye S.L. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17 (1998) 13-17
55. Poon R.T., Ho J.W., Tong C.S., Lau C., Ng I.O., and Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91 (2004) 1354-1360
56. Imura S., Miyake H., Izumi K., Tashiro S., and Uehara H. Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma. J Med Invest 51 (2004) 202-209
57. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Hicklin D.J., et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35 (2002) 834-842
58. Mitsuhashi N., Shimizu H., Ohtsuka M., Wakabayashi Y., Ito H., Kimura F., et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37 (2003) 1105-1113
59. Campbell J.S., Johnson M.M., Bauer R.L., Hudkins K.L., Gilbertson D.G., Riehle K.J., et al. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 75 (2007) 843-852
60. Campbell J.S., Hughes S.D., Gilbertson D.G., Palmer T.E., Holdren M.S., Haran A.C., et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. PNAS 102 (2005) 3389-3394
61. Lowe S.W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
62. Aguilar F., Harris C.C., Sun T., Hollstein M., and Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264 (1994) 1317-1319
63. Hofseth L.J., Saito S., Hussain S.P., Espey M.G., Miranda K.M., Araki Y., et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. PNAS 100 (2003) 143-148
64. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., and Harris C.C. TP53 and liver carcinogenesis. Hum Mutat 21 (2003) 201-216
65. Velculescu V.E. Defining the blueprint of the cancer genome. Carcinogenesis 29 (2008) 1087-1091
66. Chin L., and Gray J.W. Translating insights from the cancer genome into clinical practice. Nature 452 (2008) 553-563
67. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
68. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
69. Van Dyke T., and Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 108 (2002) 135-144
70. Sharpless N., and Depinho R. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5 (2006) 741-754
71. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., and Brinster R.L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4 (1989) 715-724
72. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 (2004) 1112-1117
73. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006) 1253-1267
74. Colnot S., Decaens T., Niwa-Kawakita M., Godard C., Hamard G., Kahn A., et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. PNAS 101 (2004) 17216-17221
75. Harada N., Oshima H., Katoh M., Tamai Y., Oshima M., and Taketo M.M. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 64 (2004) 48-54
76. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113 (2004) 1774-1783
77. Jhappan C., Stahle C., Harkins R.N., Fausto N., Smith G.H., and Merlino G.T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61 (1990) 1137-1146
78. Tonjes R.R., Lohler J., O'Sullivan J.F., Kay G.F., Schmidt G.H., Dalemans W., et al. Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene 10 (1995) 765-768
79. Tward A.D., Jones K.D., Yant S., Cheung S.T., Fan S.T., Chen X., et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. PNAS 104 (2007) 14771-14776
80. Zender L., Xue W., Zuber J., Semighini C.P., Krasnitz A., Ma B., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135 (2008) 852-864
81. Horiguchi N., Takayama H., Toyoda M., Otsuka T., Fukusato T., Merlino G., et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 21 (2002) 1791-1799
82. Sakata H., Takayama H., Sharp R., Rubin J.S., Merlino G., and LaRochelle W.J. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 7 (1996) 1513-1523
83. Tward A.D., Jones K.D., Yant S., Kay M.A., Wang R., and Bishop J.M. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol 70 (2005) 217-224
84. Wang R., Ferrell L.D., Faouzi S., Maher J.J., and Bishop J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153 (2001) 1023-1034
85. Carlson C.M., Frandsen J.L., Kirchhof N., McIvor R.S., and Largaespada D.A. Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. PNAS 102 (2005) 17059-17064
86. Klocke R., Bartels T., Jennings G., Brand K., Halter R., Strauss M., et al. Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c-myc in the liver. FASEB J 15 (2001) 1404-1406
87. Conner E.A., Lemmer E.R., Omori M., Wirth P.J., Factor V.M., and Thorgeirsson S.S. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 19 (2000) 5054-5062
88. Deane N.G., Lee H., Hamaamen J., Ruley A., Washington M.K., LaFleur B., et al. Enhanced tumor formation in cyclin D1 × transforming growth factor beta1 double transgenic mice with characterization by magnetic resonance imaging. Cancer Res 64 (2004) 1315-1322
89. Deane N.G., Parker M.A., Aramandla R., Diehl L., Lee W.J., Washington M.K., et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 61 (2001) 5389-5395
90. Farazi P., and Depinho R. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006) 674-687
91. Newell P., Villanueva A., Friedman S.L., Koike K., and Llovet J.M. Experimental models of hepatocellular carcinoma. J Hepatol 48 (2008) 858-879
92. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436 (2005) 807-811
93. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92 (1998) 3780-3792
94. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., and Lowe S.W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1 (2002) 289-298
95. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109 (2002) 335-346
96. Zender L., Xue W., Cordon-Cardo C., Hannon G.J., Lucito R., Powers S., et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol 70 (2005) 251-261
97. Camargo F.D., Gokhale S., Johnnidis J.B., Fu D., Bell G.W., Jaenisch R., et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17 (2007) 2054-2060
98. Xu M.Z., Yao T.J., Lee N.P., Ng I.O., Chan Y.T., Zender L., et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 19 (2009) 4576-4585
99. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137 (2009) 1005-1017
100. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361 (2009) 1437-1447
101. Hemann M.T., Fridman J.S., Zilfou J.T., Hernando E., Paddison P.J., Cordon-Cardo C., et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 33 (2003) 396-400
102. Xue W., Krasnitz A., Lucito R., Sordella R., Vanaelst L., Cordon-Cardo C., et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 22 (2008) 1439-1444
103. Clement P.M., Johansson H.E., Wolff E.C., and Park M.H. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 273 (2006) 1102-1114